Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 3 (2006), Issue 11 (November)

1. Trastuzumab/docetaxel-induced nail dystrophy.
   Int J Dermatol, 45(11): 1334-6. [Abstract] [Full-text]
2. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.
   Oncogene, 25(52): 6986-96. [Abstract] [Full-text]
3. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
   Clin Cancer Res, 12(21): 6326-30. [Abstract] [Full-text]
4. High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: A multicentre GEFPICS study.
   Eur J Cancer, 42(17): 2946-53. [Abstract] [Full-text]
5. Selection and characterization of Her2 binding-designed ankyrin repeat proteins.
   J Biol Chem, 281(46): 35167-75. [Abstract] [Full-text]
6. HER2 therapy: Molecular mechanisms of trastuzumab resistance.
   Breast Cancer Res, 8(6): 215. [Abstract] [Full-text]
7. A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution.
   Breast, 15(6): 728-35. [Abstract] [Full-text]
8. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
   Proc Natl Acad Sci U S A, 103(46): 17361-5. [Abstract] [Full-text]
9. Lapatinib: current status and future directions in breast cancer.
   Oncologist, 11(10): 1047-57. [Abstract] [Full-text]
10. New approaches to molecular cancer therapeutics.
    Nat Chem Biol, 2(12): 689-700. [Abstract] [Full-text]
11. C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer.
    Mol Cancer Ther, 5(11): 2919-30. [Abstract] [Full-text]
12. Distinction of benign sebaceous proliferations from sebaceous carcinomas by immunohistochemistry.
    Am J Dermatopathol, 28(6): 465-71. [Abstract] [Full-text]
13. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
    Int Immunol, 18(12): 1759-69. [Abstract] [Full-text]
14. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
    Br J Cancer, 95(11): 1504-13. [Abstract] [Full-text]

© 2004-2010 Herceptin Research Today. All Rights Reserved.